Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 244 participants.

Also called NCT04665284

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 244 participants (enrolled count) (from the registry)
Sponsor
  • Getz Pharma Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04665284
Other papers using this trial's data
  • Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial BMC endocrine disorders, 2022-11-28 DOI, PubMed 36443769, PMC9703399 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04665284. Randomized; no masking; primary purpose treatment. Start 2019-06-01 (actual); primary completion 2020-09-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus
Acronym
SAFE-PAK
Condition
Type II Diabetes Mellitus
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Usual care group
Lead sponsor
Getz Pharma (class: industry)

Record details

Record id
cardio:ct-nct04665284
Content hash
aef8728bf4eef9e89de5647210d2385bf02e63c5d0a34af321dfe69da1139d64